To enhance tumor targeting, Zhu et al. combined an MMP2-sensitive PEG-lipid conjugate with antibody targeting and an intracellular penetrating moiety (TaT peptide) [294] combining long circulation by PEGylation, tumor targeting via antinuclear antibody 2C5, and selective internalization by tumor cells through MMP-2 triggered exposure of TaT peptide. Here, MMP2 is linked to neoplasm.